Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 178 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Injection of autologous stem cells Clear all
Completed Phase 1 Interventional Results available

Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis (FOCUS Br)

NCT00314366
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Stem Cell Therapy, Control (plasma)
Biological · Other
Lead sponsor
Texas Heart Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

NCT02703779
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Granulocyte colony-stimulating factor (G-CSF), Mozobil
Drug
Lead sponsor
Siddhartha Ganguly
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas

NCT00001566
View directory record Official record
Conditions
Ewing's Sarcoma, Rhabdomyosarcoma
Interventions
therapeutic autologous dendritic cells, indinavir sulfate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 35 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy (SCIPIO)

NCT00474461
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure
Interventions
Treatment group
Biological
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma

NCT00596154
View directory record Official record
Conditions
CNS Lymphoma, CNS Brain Cancer, Non-Hodgkin's Lymphoma
Interventions
Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 72 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2023
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2024 · Synced Sep 23, 2026, 4:32 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee

NCT02844751
View directory record Official record
Conditions
Osteoarthritis
Interventions
[StroMed + platelet rich plasma (PRP)], [PRP] platelet rich plasma
Biological
Lead sponsor
VivaTech International, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Grove City, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 23, 2026, 4:32 AM EDT
Recruiting Phase 1 Interventional

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

NCT03909412
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Cyclophosphamide, Dexamethasone, Granulocyte Colony-Stimulating Factor
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 23, 2026, 4:32 AM EDT
Withdrawn Phase 2 Interventional

2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma

NCT03168100
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2019 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium

NCT00548613
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Arteriosclerosis, Coronary Atherosclerosis, Coronary Disease
Interventions
MESENDO
Biological
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Sep 23, 2026, 4:32 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Autologous Adipose-Derived Stromal Cells Delivered Into the Corpus Cavernous in Patients With Erectile Dysfunction

NCT02087397
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Liposuction, AD-SVF Cell Injection
Other · Biological
Lead sponsor
Ageless Regenerative Institute
Industry
Eligibility
18 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 23, 2026, 4:32 AM EDT
Active, not recruiting Phase 1 Interventional

Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA

NCT03608579
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Autologous Adipose Derived Mesenchymal Stromal Cells
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 2 Interventional

Adipose Derived Regenerative Cellular Therapy of Chronic Wounds

NCT02092870
View directory record Official record
Conditions
Diabetic Foot, Venous Ulcer, Pressure Ulcer
Interventions
Adipose derived stem cells
Drug
Lead sponsor
Tower Outpatient Surgical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

Stem Cell Injection for Peripheral Vascular Disease

NCT00278603
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Stem Cell Transplantation
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia

NCT00049517
View directory record Official record
Conditions
Leukemia
Interventions
sargramostim, busulfan, cyclophosphamide, cytarabine, gemtuzumab ozogamicin (GO), Daunorubicin, Autologous HCT, Allogeneic HCT
Biological · Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
16 Years to 60 Years
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2019
U.S. locations
98
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Results available

Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

NCT02658968
View directory record Official record
Conditions
Relapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Betalutin
Drug
Lead sponsor
Nordic Nanovector
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Not applicable Interventional Results available

Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma

NCT01050790
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Azacitidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 69 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 23, 2026, 4:32 AM EDT
Recruiting Phase 1 Interventional

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

NCT06514898
View directory record Official record
Conditions
Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
Interventions
TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Td vaccine, autologous HSCs, Pembrolizumab
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
4 Years to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Not applicable Interventional

Adipose Cells for Degenerative Disc Disease

NCT02097862
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Adipose Stem Cells
Procedure
Lead sponsor
Bioheart, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Sunrise, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions

NCT01953523
View directory record Official record
Conditions
Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases, Cardiomyopathies, Emphysema
Interventions
Administration of autologous adipose derived SVF
Procedure
Lead sponsor
Elliot Lander
Industry
Eligibility
16 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Not applicable Interventional

Autologous Bone Marrow Mononuclear Cell Implantation for Moderate to Severe Peripheral Arterial Disease

NCT00919516
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Bone marrow mononuclear cell implantation
Procedure
Lead sponsor
The Vascular and Vein Center, Columbus, OH
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 23, 2026, 4:32 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Autologous Volar Fibroblast Injection Into the Stump Site of Amputees

NCT03947450
View directory record Official record
Conditions
Amputation, Skin Wound, Stem Cell
Interventions
Autologous Skin Fibroblasts, Placebo
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 23, 2026, 4:32 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Adipose Derived Stem Cell Therapy for Autism

NCT01502488
View directory record Official record
Conditions
Autism
Interventions
Fat Harvesting and Stem Cell Injection
Procedure
Lead sponsor
Ageless Regenerative Institute
Industry
Eligibility
3 Years to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 23, 2026, 4:32 AM EDT
Withdrawn Phase 1 Interventional

Stem Cell Therapy as Adjunct to Revascularization

NCT00463853
View directory record Official record
Conditions
Coronary Arteriosclerosis, Coronary Artery Bypass Graft, Myocardial Revascularization
Interventions
Autologous stem cell therapy, CABG, CMRI
Procedure · Radiation
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 23, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Results available

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

NCT01175356
View directory record Official record
Conditions
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, External Beam Radiation Therapy, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Iobenguane I-131, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Pharmacological Study, Questionnaire Administration, Therapeutic Conventional Surgery, Topotecan Hydrochloride, Vincristine Sulfate
Radiation · Procedure · Drug + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 23, 2026, 4:32 AM EDT